Go to Top

Recent Updates

For Biotech and Pharmaceutical Companies

Looking for Financing, PR or Investor Relations Services?

We facilitate introductions to leading hedge funds who share your company's best interests and may be interested in investing in you. We also bump shoulders with some of the premier Investor Relations & PR firms in the United States. We've a track record of success which supports these relationships, and a network that feeds our success. If you have a company in need of greater visibility or capital investment, we'd like to hear from you.

Biotech News and Updates

Sientra (NASDAQ: SIEN) : DD and More

A few excerpts:


From Sientra’s (SIEN) 8-K filing from October 30th, 2015:
We continue to be well funded with a cash and cash equivalents balance of $148.9 million as of September 30, 2015. Earlier

Read More

BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases.

BioCryst announced that it received a preliminary comment letter from the FDA that

Read More

AntriaBio (ANTB): An Opportunity

Novo Nordisk – the world ‘s largest insulin producer – and major diabetes drug manufacturers – could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment.

Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi’ s $6 BILLION-A-YEAR basal insulin – ‘Lantus’ – OBSOLETE.

The Company that ‘s making executives in the world’ s largest pharmaceutical firms sweat is Menlo Park, California-based ANTRIABIO, INC. (ANTB)

Here ‘s why large pharma is worried about ANTRIABIO’ s technology:


Read More




Biotech Stocks Reviews